We provide you with 20 years of free, institutional-grade data for BYSI stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BYSI. Explore the full financial landscape of BYSI stock.
| Reported Date | CIK | Ticker | Type |
|---|
BeyondSpring Inc(NASDAQ:BYSI) 
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination...
Website: http://www.beyondspringpharma.com
Founded: 2010
Full Time Employees: 61
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about BYSI stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.